Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid Leukemia Acquisition brings a new therapeutic mechanism to Amgen's ...
Amgen's acquisition of Dark Blue Therapeutics focuses on DBT 3757, a promising therapy for AML and ALL, valued at over $840 million. DBT 3757 targets MLLT1/3 proteins, offering potential as a first-in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results